Fluctuations or downward pressures on Apogee stock generally do not reflect organic business deterioration, but rather minor market discounts relative to the definitive all-cash buyout price established by AbbVie. Small spreads between current trading prices and the final acquisition cash offer typically account for the time value of money and minor regulatory closure uncertainties prior to the final merger closing date.